These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 2860255)

  • 1. Prevention of coronary heart disease in practice. Implications of the results of recent clinical trials.
    Borhani NO
    JAMA; 1985 Jul; 254(2):257-62. PubMed ID: 2860255
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical trials of antiplatelet drug therapy in acute myocardial infarction, unstable angina, and aortocoronary bypass surgery.
    Cairns JA
    Cardiovasc Clin; 1987; 18(1):231-46. PubMed ID: 3300983
    [No Abstract]   [Full Text] [Related]  

  • 3. Secondary prevention of coronary events after myocardial infarction. Beta-blockers and/or anti-platelets: to whom, when and for how long. A review.
    Bélanger GL; Lavallée JP; Lenis J; Ouellet CA
    Can J Cardiol; 1985 Mar; 1(2):97-105. PubMed ID: 2864991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prevention of myocardial infarction by chemotherapy].
    Toshima H; Adachi K
    Nihon Rinsho; 1982; 40(11):2465-70. PubMed ID: 6130172
    [No Abstract]   [Full Text] [Related]  

  • 5. Aspirin for the prevention of coronary thrombosis: current facts and perspectives.
    Patrono C
    Eur Heart J; 1986 Jun; 7(6):454-9. PubMed ID: 3525167
    [No Abstract]   [Full Text] [Related]  

  • 6. Role of platelet-active drugs in coronary artery disease.
    Sherry S
    Cardiovasc Clin; 1983; 14(1):173-89. PubMed ID: 6352025
    [No Abstract]   [Full Text] [Related]  

  • 7. A perspective on platelet-suppressant drug treatment in coronary artery and cerebrovascular disease.
    Genton E
    Circulation; 1980 Dec; 62(6 Pt 2):V111-21. PubMed ID: 6108166
    [No Abstract]   [Full Text] [Related]  

  • 8. Secondary prevention of coronary heart disease.
    Kornitzer M
    Acta Cardiol; 1984; 39(4):235-40. PubMed ID: 6148826
    [No Abstract]   [Full Text] [Related]  

  • 9. [Sliding indications for balloon angioplasty].
    Bonnier JJ; Post D
    Ned Tijdschr Geneeskd; 1994 Jul; 138(30):1505-7. PubMed ID: 7915009
    [No Abstract]   [Full Text] [Related]  

  • 10. Beta receptor blocking agents in the secondary prevention of coronary heart disease.
    Vedin JA; Wilhelmsson CE
    Annu Rev Pharmacol Toxicol; 1983; 23():29-44. PubMed ID: 6135389
    [No Abstract]   [Full Text] [Related]  

  • 11. Platelets and prostaglandins in sudden death: therapeutic implications.
    Gelman JS; Mehta J
    Cardiovasc Clin; 1985; 15(3):65-80. PubMed ID: 2870807
    [No Abstract]   [Full Text] [Related]  

  • 12. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events).
    Bowker TJ; Clayton TC; Ingham J; McLennan NR; Hobson HL; Pyke SD; Schofield B; Wood DA
    Heart; 1996 Apr; 75(4):334-42. PubMed ID: 8705756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiplatelet drugs in the secondary prevention of myocardial infarction. One view of the present position.
    McNicol GP
    Lancet; 1980 Oct; 2(8197):736-8. PubMed ID: 6106840
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of prostaglandin-mediated platelet-suppressant drugs on acute cardiovascular catastrophes.
    Sherry S
    Adv Prostaglandin Thromboxane Leukot Res; 1982; 10():173-210. PubMed ID: 6216782
    [No Abstract]   [Full Text] [Related]  

  • 15. Cardiac death prevention in post-myocardial infarction patients: a review.
    Boissel JP; Leizorovicz A; Faucomprez C
    Acta Cardiol Suppl; 1980; (25):147-79. PubMed ID: 6103625
    [No Abstract]   [Full Text] [Related]  

  • 16. Antiplatelet agents: rationale and results.
    Kelton JG
    Clin Haematol; 1983 Feb; 12(1):311-54. PubMed ID: 6132693
    [No Abstract]   [Full Text] [Related]  

  • 17. Recent advances in the secondary prevention of coronary heart disease.
    Veverka A; Jolly JL
    Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):877-89. PubMed ID: 15500433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Summary of ongoing clinical trials of platelet-active drugs in cardiovascular disease.
    Passamani ER
    Circulation; 1980 Dec; 62(6 Pt 2):V106-10. PubMed ID: 7002348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Aftercare of heart infarct patients to reduce the risk of a subsequent infarction].
    Offerhaus L
    Ned Tijdschr Geneeskd; 1983 Apr; 127(16):673-9. PubMed ID: 6134240
    [No Abstract]   [Full Text] [Related]  

  • 20. [Results of ambulatory follow-up of patients after myocardial infarction treated with platelet aggregation inhibitors and antithrombotic drugs].
    Markiewicz M; Rymar B; Florkiewicz H; Wysokiński A
    Pol Tyg Lek; 1983 Nov; 38(48):1501-3. PubMed ID: 6382203
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.